[Featured Stock] Jeil Pharm Leads with 'Nafamostat' COVID-19 Cure... 'Strong Rise'
[Asia Economy Reporter Yoo Hyun-seok] Jeil Pharmaceutical is showing strong performance. The news that Nafamostat is also effective for patients with the novel coronavirus infection (COVID-19) appears to have had an impact.
As of 10:20 AM on the 4th, Jeil Pharmaceutical was trading at 58,900 KRW, up 6.90% (3,800 KRW).
On the same day, a media outlet reported that Professors Lee Ji-young and Jang Seok-bin from the Department of Infectious Diseases at Dankook University Hospital conducted clinical treatment using Nafamostat on three confirmed COVID-19 patients, all of whom were fully cured without side effects.
Dankook University Hospital is known to be one of the 10 hospitals approved by the Ministry of Food and Drug Safety for clinical treatment based on research results from the Korea Pasteur Institute.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Last Year, Net Profit of Securities Firms' Overseas Subsidiaries Rose from $270 Million to $450 Million
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
Jeil Pharmaceutical holds a generic license for Nafamostat developed by the Japanese pharmaceutical company Torii and sells treatments such as acute pancreatitis medication.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
